Gout & Uric Acid Explained: Flares, Kidney Risk, and the Metabolic Connection

Educational disclaimer: This article provides general health education based on published clinical guidelines and research. It is not medical advice and cannot diagnose, prescribe, or replace a consultation with a qualified clinician. Do not start, stop, or change any medication based on this article. If you have concerns about gout or uric acid levels, speak with your doctor.

Urate crystals from a gout tophus under light microscopy. In gout, monosodium urate crystals deposit in joints and soft tissues, triggering intense inflammatory flares.

What Gout Is

Gout is a form of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and surrounding tissues. When uric acid levels in the blood remain elevated over time, urate can crystallise and accumulate — and when those crystals trigger an immune response, the result is an intensely painful flare.

Gout is the most common inflammatory arthritis, affecting approximately 3–4% of adults in high-income countries. Its prevalence is rising globally, driven by increasing rates of obesity, metabolic syndrome, and dietary changes.

Gout is not simply a "joint disease." It is increasingly understood as a systemic metabolic condition with important connections to kidney disease, cardiovascular disease, diabetes, and metabolic syndrome.

How Uric Acid Works

Uric acid is the final breakdown product of purines — molecules found in your body's cells and in certain foods. Humans lack the enzyme uricase (which other mammals use to break uric acid down further), so we must excrete it:

• About two-thirds of uric acid is excreted by the kidneys.
• About one-third is eliminated through the gut.

Hyperuricaemia — elevated serum urate — is defined as levels above approximately 6.8 mg/dL (408 µmol/L), the physicochemical saturation point at which MSU crystals can form. However:

• Not everyone with hyperuricaemia develops gout. Many people have elevated uric acid for years without ever having a flare. This is called asymptomatic hyperuricaemia.
• Underexcretion (the kidneys not clearing enough urate) accounts for about 90% of hyperuricaemia. Overproduction accounts for about 10%.
• Serum urate can be normal during an acute flare — a single reading does not confirm or exclude gout.

Why Gout Signals Broader Metabolic Risk

Gout rarely exists in isolation. The same metabolic environment that produces hyperuricaemia also drives other serious conditions:

• Metabolic syndrome — the majority of people with gout have metabolic syndrome (central obesity, hypertension, dyslipidaemia, insulin resistance). Insulin resistance directly reduces renal urate excretion, creating a vicious cycle.
• Cardiovascular disease — gout is independently associated with increased risk of heart attack, stroke, and cardiovascular death. The chronic inflammation and metabolic dysfunction contribute to accelerated atherosclerosis.
• Type 2 diabetes — hyperuricaemia is associated with increased risk of developing diabetes, and diabetes worsens gout management.
• Hypertension — elevated uric acid is associated with incident hypertension, particularly in younger adults. Many antihypertensive medications (especially diuretics) also raise urate levels.
• Chronic kidney disease — a bidirectional relationship. CKD reduces urate clearance (worsening hyperuricaemia), and hyperuricaemia may contribute to kidney damage through crystal deposition and vascular effects.

This means that a gout diagnosis should prompt evaluation of the full metabolic picture — not just the joints.

The Kidney Connection

The kidneys are central to uric acid balance, and the relationship between gout and kidney disease runs in both directions:

• Reduced kidney function → higher urate: As GFR declines in CKD, the kidneys excrete less uric acid. Hyperuricaemia is extremely common in advanced CKD.
• Uric acid kidney stones: Approximately 10% of all kidney stones are composed of uric acid. Risk increases with low urine pH, low urine volume, and high uric acid excretion.
• Urate nephropathy: In rare cases (typically tumour lysis syndrome or severe overproduction), massive urate crystal deposition can cause acute kidney injury.
• Does treating hyperuricaemia protect kidneys? This remains debated. Some trials (e.g., CKD-FIX, PERL) did not show that allopurinol slowed CKD progression. Current guidelines (KDIGO 2024) do not recommend routine urate-lowering therapy for CKD without clinical gout.

If you have both gout and kidney disease, your clinician will need to consider both conditions when choosing medications and monitoring intervals.

Who Is At Higher Risk

• Male sex — men develop gout much more commonly than premenopausal women. Oestrogen promotes renal urate excretion, so risk equalises somewhat after menopause.
• Age — risk increases with age in both sexes.
• Obesity and central adiposity — strongly associated with hyperuricaemia and gout through insulin resistance and increased purine turnover.
• Diet — high intake of purine-rich foods (organ meats, certain seafood), alcohol (especially beer and spirits), and fructose-sweetened beverages increases risk. However, diet alone rarely causes gout without underlying metabolic or genetic predisposition.
• Alcohol — beer is highest risk (contains purines and raises urate through multiple mechanisms). Spirits also increase risk. Wine appears to have a smaller effect at moderate intake.
• Medications — thiazide and loop diuretics, low-dose aspirin, ciclosporin, and some other drugs raise serum urate.
• Chronic kidney disease — reduced urate clearance.
• Genetics — variants in urate transporter genes (SLC2A9, ABCG2) significantly influence serum urate levels and gout risk. Family history is a meaningful risk factor.
• Other conditions — psoriasis, myeloproliferative disorders, organ transplant recipients.

What A Gout Flare Looks Like

A classic acute gout flare:

• Rapid onset — often reaches maximum intensity within 12–24 hours, frequently starting at night.
• Severe pain — often described as the worst joint pain experienced. Even light touch (bedsheet contact) can be excruciating.
• Single joint — most commonly the base of the big toe (first metatarsophalangeal joint, or "podagra"). Also common in midfoot, ankle, knee, wrist, and finger joints.
• Swelling, redness, warmth — the joint appears inflamed and may be visibly swollen and red.
• Self-limiting — untreated flares typically resolve within 1–2 weeks, but treatment shortens duration and reduces severity.

Between flares (intercritical gout), joints may feel normal — but MSU crystals remain deposited. Without treatment, flares tend to become more frequent, last longer, and involve more joints over time.

In advanced untreated gout, visible tophi (chalky deposits of urate crystite) can form under the skin — commonly on ears, fingers, elbows, and around joints. Chronic tophaceous gout can cause joint destruction.

How Clinicians Diagnose Gout

• Joint aspiration (gold standard) — a needle is used to withdraw fluid from the affected joint. Under polarised light microscopy, MSU crystals appear as needle-shaped, negatively birefringent crystals. This definitively confirms gout and excludes septic arthritis.
• Serum uric acid — supportive but not diagnostic alone. Can be normal during a flare. Persistently elevated levels support the diagnosis in the right clinical context.
• Imaging — ultrasound can show the "double-contour sign" (urate deposition on cartilage surface). Dual-energy CT (DECT) can detect urate deposits throughout the body. Plain X-rays are often normal early but may show erosions in chronic gout.
• Clinical criteria — the 2015 ACR/EULAR classification criteria use a scoring system combining clinical features, lab values, and imaging when joint aspiration is not performed.

What Usually Helps Reduce Risk

These are population-level approaches supported by clinical evidence. Discuss what is appropriate for your situation with your clinician.

• Weight management — gradual weight loss reduces serum urate and flare frequency. Avoid crash diets or fasting, which can paradoxically trigger flares through rapid purine turnover and ketosis.
• Dietary pattern — rather than obsessing over individual "high-purine" foods, evidence supports overall dietary quality. DASH-style and Mediterranean patterns are associated with lower gout risk. Reducing organ meats, certain shellfish, and processed meats is reasonable.
• Alcohol moderation — limiting beer and spirits reduces flare risk. Complete abstinence is not required for everyone, but alcohol is a modifiable trigger.
• Limit fructose-sweetened beverages — sugar-sweetened soft drinks and fruit juices with added fructose increase urate production.
• Hydration — adequate fluid intake supports renal urate excretion and reduces kidney stone risk.
• Manage metabolic comorbidities — optimising blood pressure, blood sugar, and lipids addresses the shared metabolic drivers.
• Medication review — if you take diuretics or other urate-raising medications, discuss alternatives with your clinician. Do not stop medications without medical guidance.

There is no single "gout diet" that cures the condition. Dietary changes alone rarely normalise uric acid in people with established gout — most will need pharmacological urate-lowering therapy if they have recurrent flares.

What Clinicians May Discuss

This is an overview of treatment approaches — not a recommendation to start or change any treatment. All decisions require individual clinical assessment.

Acute Flare Management

The goal is rapid pain relief and inflammation control. Options clinicians may use include:

• Colchicine — most effective when started early in a flare.
• NSAIDs — anti-inflammatory painkillers (with consideration of kidney function and cardiovascular risk).
• Corticosteroids — oral, injected into the joint, or intramuscular; useful when NSAIDs or colchicine are contraindicated.

Urate-Lowering Therapy (ULT)

For people with recurrent flares, tophi, or urate-related kidney damage, clinicians may discuss long-term therapy to reduce serum urate below the crystallisation threshold:

• Allopurinol — the most commonly used ULT worldwide. A xanthine oxidase inhibitor that reduces uric acid production.
• Febuxostat — an alternative xanthine oxidase inhibitor, sometimes used when allopurinol is not tolerated.
• Probenecid — a uricosuric agent that increases renal urate excretion. Requires adequate kidney function.
• Treat-to-target — guidelines recommend titrating ULT to achieve serum urate below 6 mg/dL (360 µmol/L), or below 5 mg/dL for tophaceous gout.
• Prophylaxis during ULT initiation — starting ULT can paradoxically trigger flares as crystals dissolve. Low-dose anti-inflammatory prophylaxis is typically co-prescribed for the first months.
• Pegloticase — a biologic enzyme for severe refractory gout unresponsive to conventional ULT. Administered by infusion in specialist settings.

Do not start, stop, or adjust any medication based on this article. ULT is a long-term commitment and requires monitoring of urate levels, kidney function, and potential side effects under clinical supervision.

When To Seek Urgent Help

Most gout flares, while painful, are managed in outpatient settings. However, seek prompt medical attention if:

• Fever with a hot, swollen joint — septic arthritis (joint infection) can mimic gout and is a medical emergency. Joint aspiration is needed to distinguish the two. Do not assume a hot joint is "just gout" if fever is present.
• Severe flank pain with blood in urine — may indicate a uric acid kidney stone (renal colic) requiring urgent evaluation.
• Signs of worsening kidney function — reduced urine output, significant swelling, nausea, or confusion in someone with known CKD and gout.
• Recurrent or prolonged flares despite treatment — may indicate inadequate urate control or an alternative diagnosis requiring specialist review.
• First-ever acute joint attack — should be evaluated by a clinician to confirm the diagnosis and exclude other causes (infection, pseudogout, reactive arthritis).

Questions To Ask Your Doctor

• My uric acid is elevated — does this mean I have gout, or could it be asymptomatic hyperuricaemia?
• Should I start urate-lowering therapy, or can we manage with lifestyle changes for now?
• How does my gout connect to my kidney function / blood pressure / diabetes management?
• Are any of my current medications raising my uric acid levels?
• What is my target serum urate level, and how often should it be checked?
• What should I do at the first sign of a flare to reduce its severity?
• Should I have my kidney function monitored given my gout history?
• Are there dietary changes that would meaningfully help in my specific situation?

Sources

• FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for Management of Gout. Arthritis Care Res. 2020.
• Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017.
• Dalbeth N, et al. Gout. Lancet. 2021.
• NIH/NIAMS. Gout. niams.nih.gov
• NIDDK. Kidney Stones. niddk.nih.gov
• CDC. Gout. cdc.gov
• NHS. Gout. nhs.uk
• KDIGO 2024 Clinical Practice Guideline for the Management of CKD.
• Neogi T, et al. 2015 Gout Classification Criteria. Arthritis Rheumatol. 2015.